Maxim Group analyst Naz Rahman maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $325.00. The company's shares closed last Friday at $288.03, close to its 52-week high of $296.84. According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.5% and a 26.8% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Clarus Therapeutics Holdings, and Virpax Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $299.
https://www.tipranks.com/news/blurbs/maxim-group-believes-vertex-pharmaceuticals-vrtx-still-has-room-to-grow?utm_source=advfn.com&utm_medium=referral